{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T19:05:43Z","timestamp":1789067143649,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To report a real-world analysis of switching to faricimab in the setting of neovascular age-related macular degeneration (nAMD), with regards to fluid volumes on optical coherence tomography (OCT), treatment interval, and best corrected visual acuity (BCVA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively collected the OCT scans of all eyes that were being treated with anti-vascular endothelial growth factor (VEGF) therapy and were switched to faricimab in clinical the practices of eight retina specialists at five clinics in three Australian states (CORRNet Study Group; Clinical Ophthalmologists\u2019 Real-world Research Network). Only those that remained on faricimab are the subject of this report. All OCT scans were analyzed for both the presence and volume of intraretinal fluid (IRF) and subretinal fluid (SRF) using machine learning (ML) algorithms (Macuject Pty Ltd, Melbourne, Australia).\u00a0Mean interval time between injections and BCVA were recorded at the time of switch and after the switch to faricimab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 3082 eyes of 2200 patients treated with intravitreal anti-VEGF injections for nAMD, 473 eyes (84.0% of those switched to faricimab) remained on faricimab and thus met the criteria to be included in the analysis. At the time of switch to faricimab the number of eyes having IRF, either alone or in combination with SRF, was 142 (30.0%) and the number of eyes with SRF, either alone or in combination with IRF, was 223 (47.2%).<\/jats:p>\n                    <jats:p>\n                      Following the switch to faricimab, for the 142 eyes with any IRF, 115 eyes (80.9%) had a reduction in IRF volume, and of the 223 eyes with SRF, 190 eyes (85.2%) had a reduction in SRF volume, and 64 of the 69 (92.8%) eyes with both IRF and SRF present had a reduction in both fluid subtypes.\u00a0The interval distribution shifted from a mean of 5.78\u2009\u00b1\u20091.92 (SD) to 6.91\u2009\u00b1\u20092.26 (SD) weeks over the study period (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\u00a0The mean BCVA improved from 63.91\u2009\u00b1\u200920.03 logMar letters to 69.25\u2009\u00b1\u200917.38 logMar letters (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) after the switch.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Switching to faricimab in eyes with nAMD previously treated with other anti-VEGF agents was associated with anatomical and functional improvements in this selected cohort. Further prospective studies including the comparison with other anti-VEGF agents are warranted to more definitively evaluate the clinical benefits of faricimab in this setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00417-025-06931-5","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T02:44:33Z","timestamp":1755485073000},"page":"3097-3103","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The impact of swithching faricimab in the treatment of neovascular age-related macular degeneration: a real-world analysis"],"prefix":"10.1007","volume":"263","author":[{"given":"Giacomo","family":"Boscia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devinder","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Corradetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles P.","family":"O\u2019Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gihan","family":"Samarasinghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophiana M.","family":"Lindenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Urrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Mauger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giang","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muneeswar","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4939-3306","authenticated-orcid":false,"given":"SriniVas R.","family":"Sadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,18]]},"reference":[{"key":"6931_CR1","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","volume":"390","author":"T Vos","year":"2017","unstructured":"Vos T, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, Abdulkader RS, Abdulle AM, Abebo TA, Abera SF, Aboyans V (2017) Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: a systematic analysis for the global burden of disease study 2016. Lancet 390:1211\u20131259. https:\/\/doi.org\/10.1016\/S0140-6736(17)32154-2","journal-title":"Lancet"},{"key":"6931_CR2","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1002\/phar.1264","volume":"33","author":"LK Cheung","year":"2013","unstructured":"Cheung LK, Eaton A (2013) Age-related macular degeneration. Pharmacotherapy 33:838\u2013855. https:\/\/doi.org\/10.1002\/phar.1264","journal-title":"Pharmacotherapy"},{"key":"6931_CR3","first-page":"74","volume":"59","author":"A Gheorghe","year":"2015","unstructured":"Gheorghe A, Mahdi L, Musat O (2015) Age-related macular degeneration. Rom J Ophthalmol 59:74\u201377","journal-title":"Rom J Ophthalmol"},{"key":"6931_CR4","doi-asserted-by":"publisher","first-page":"e000398","DOI":"10.1136\/bmjophth-2019-000398","volume":"4","author":"S Khanna","year":"2019","unstructured":"Khanna S, Komati R, Eichenbaum DA et al (2019) Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review. BMJ Open Ophthalmol 4:e000398. https:\/\/doi.org\/10.1136\/bmjophth-2019-000398","journal-title":"BMJ Open Ophthalmol"},{"key":"6931_CR5","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/aos.15783","volume":"102","author":"E Vinge","year":"2024","unstructured":"Vinge E, Bro T (2024) Treatment burden on patients receiving intravitreal anti-VEGF for wet age-related macular degeneration. Acta Ophthalmol 102:478\u2013482. https:\/\/doi.org\/10.1111\/aos.15783","journal-title":"Acta Ophthalmol"},{"key":"6931_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2017.07.014","volume":"125","author":"R Silva","year":"2018","unstructured":"Silva R, Berta A, Larsen M et al (2018) Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the TREND study. Ophthalmology 125:57\u201365. https:\/\/doi.org\/10.1016\/j.ophtha.2017.07.014","journal-title":"Ophthalmology"},{"key":"6931_CR7","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","volume":"403","author":"P Lanzetta","year":"2024","unstructured":"Lanzetta P, Korobelnik J-F, Heier JS et al (2024) Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet 403:1141\u20131152. https:\/\/doi.org\/10.1016\/S0140-6736(24)00063-1","journal-title":"Lancet"},{"key":"6931_CR8","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"PU Dugel","year":"2020","unstructured":"Dugel PU, Koh A, Ogura Y et al (2020) HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 127:72\u201384. https:\/\/doi.org\/10.1016\/j.ophtha.2019.04.017","journal-title":"Ophthalmology"},{"key":"6931_CR9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","volume":"121","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Kaiser PK, Korobelnik J-F et al (2014) Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 121:193\u2013201. https:\/\/doi.org\/10.1016\/j.ophtha.2013.08.011","journal-title":"Ophthalmology"},{"key":"6931_CR10","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C et al (2022) Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet 399:729\u2013740. https:\/\/doi.org\/10.1016\/S0140-6736(22)00010-1","journal-title":"Lancet"},{"key":"6931_CR11","doi-asserted-by":"publisher","first-page":"eaau6732","DOI":"10.1126\/sciadv.aau6732","volume":"5","author":"J Kim","year":"2019","unstructured":"Kim J, Park JR, Choi J et al (2019) Tie2 activation promotes choriocapillary regeneration for alleviating neovascular age-related macular degeneration. Sci Adv 5:eaau6732. https:\/\/doi.org\/10.1126\/sciadv.aau6732","journal-title":"Sci Adv"},{"key":"6931_CR12","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1001\/jamaophthalmol.2020.2699","volume":"138","author":"AM Khanani","year":"2020","unstructured":"Khanani AM, Patel SS, Ferrone PJ et al (2020) Efficacy of every four monthly and quarterly dosing of faricimab vs ranibizumab in neovascular age-related macular degeneration: the STAIRWAY phase 2 randomized clinical trial. JAMA Ophthalmol 138:964\u2013972. https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.2699","journal-title":"JAMA Ophthalmol"},{"key":"6931_CR13","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1038\/s41433-023-02553-5","volume":"37","author":"AM Khanani","year":"2023","unstructured":"Khanani AM, Aziz AA, Khan H et al (2023) The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study \u2013 6 month results. Eye (Basingstoke) 37:3574\u20133581. https:\/\/doi.org\/10.1038\/s41433-023-02553-5","journal-title":"Eye (Basingstoke)"},{"issue":"15","key":"6931_CR14","doi-asserted-by":"publisher","first-page":"5145","DOI":"10.3390\/jcm12155145","volume":"12","author":"M Kishi","year":"2023","unstructured":"Kishi M, Miki A, Kamimura A et al (2023) Short-term outcomes of faricimab treatment in aflibercept-refractory eyes with neovascular age-related macular degeneration. J Clin Med 12(15):5145. https:\/\/doi.org\/10.3390\/jcm12155145","journal-title":"J Clin Med"},{"key":"6931_CR15","doi-asserted-by":"publisher","unstructured":"Sim SY, Chalkiadaki E, Koutsocheras G, et al (2024) Real-world 1-year outcomes of treatment-intensive neovascular age-related macular degeneration switched to faricimab. Ophthalmol Retina. https:\/\/doi.org\/10.1016\/j.oret.2024.07.020","DOI":"10.1016\/j.oret.2024.07.020"},{"key":"6931_CR16","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1097\/IAE.0000000000003194","volume":"41","author":"PK Kaiser","year":"2021","unstructured":"Kaiser PK, Wykoff CC, Singh RP et al (2021) Retinal fluid and thickness as measures of disease activity in neovascular age-related macular degeneration. Retina 41:1579\u20131586. https:\/\/doi.org\/10.1097\/IAE.0000000000003194","journal-title":"Retina"},{"key":"6931_CR17","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","volume":"127","author":"RF Spaide","year":"2020","unstructured":"Spaide RF, Jaffe GJ, Sarraf D et al (2020) Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group. Ophthalmology 127:616\u2013636. https:\/\/doi.org\/10.1016\/j.ophtha.2019.11.004","journal-title":"Ophthalmology"},{"key":"6931_CR18","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ophtha.2018.11.025","volume":"126","author":"RH Guymer","year":"2019","unstructured":"Guymer RH, Markey CM, McAllister IL et al (2019) Tolerating subretinal fluid in neovascular age-related macular degeneration treated with ranibizumab using a treat-and-extend regimen: FLUID study 24-month results. Ophthalmology 126:723\u2013734. https:\/\/doi.org\/10.1016\/j.ophtha.2018.11.025","journal-title":"Ophthalmology"},{"key":"6931_CR19","first-page":"2276","volume":"65","author":"SB Velaga","year":"2024","unstructured":"Velaga SB, Nittala MG, Samarasinghe G et al (2024) Accuracy of automated subretinal fluid volume quantification using the macuject algorithm. Invest Ophthalmol Vis Sci 65:2276","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6931_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-024-82746-4","volume":"15","author":"HY Han","year":"2025","unstructured":"Han HY, Park SM, Lee JH et al (2025) Outcomes and predictive factors for fluid resolution following three loading injections of faricimab for treatment-na\u00efve neovascular age-related macular degeneration. Sci Rep 15:1\u201310. https:\/\/doi.org\/10.1038\/s41598-024-82746-4","journal-title":"Sci Rep"},{"key":"6931_CR21","doi-asserted-by":"publisher","first-page":"100456","DOI":"10.1016\/J.XOPS.2023.100456","volume":"4","author":"K Kostolna","year":"2024","unstructured":"Kostolna K, Reiter GS, Frank S et al (2024) A systematic prospective comparison of fluid volume evaluation across OCT devices used in clinical practice. Ophthalmol Sci 4:100456. https:\/\/doi.org\/10.1016\/J.XOPS.2023.100456","journal-title":"Ophthalmol Sci"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-06931-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-025-06931-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-06931-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:12:49Z","timestamp":1781608369000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-025-06931-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,18]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["6931"],"URL":"https:\/\/doi.org\/10.1007\/s00417-025-06931-5","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,18]]},"assertion":[{"value":"8 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Vas Sadda although the author is the Editor of the journal, there was no involvement with the peer review process for this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Editorial conflict of interest"}},{"value":"No human participants and\/or animals are involved in this research. An Institutional Review Board (IRB of University of Bari) established that, given that there were no human participants in the study, it was exempt from IRB oversight.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"No Conflicts of Interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}